{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:36:37Z","timestamp":1793864197415,"version":"4.6.1"},"reference-count":35,"publisher":"BMJ","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"unspecified","delay-in-days":309,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Reg Anesth Pain Med"],"accepted":{"date-parts":[[2024,12,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Although the prevalence of chemotherapy-induced peripheral neuropathy (CIPN) has been reported, the proportion of patients with CIPN who report chronic moderate-to-severe neuropathy or chronic painful neuropathy remains poorly understood, despite its significant impact on patients\u2019 quality of life and treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The primary outcome was the pooled prevalence of chronic (\u22653 months) moderate-to-severe CIPN or painful CIPN among patients diagnosed with CIPN. Estimates from each study were transformed using a double-arcsine transformation and pooled in a meta-analysis using an inverse variance heterogeneity model. Subgroup analysis was conducted based on geographical region, sex, chemotherapy regimen, primary cancer type, and funding source; metaregression analysis was conducted based on study design, human development index (HDI), and publication year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      76 studies from 29 countries, encompassing 13\u2009635 patients with CIPN, were included. Among patients diagnosed with CIPN, the pooled prevalence of those reporting chronic moderate-to-severe CIPN or painful CIPN was estimated at 47.76% (95% CI 37.50 to 58.08; 95% prediction interval 24.68\u201371.84). Substantial heterogeneity was observed across studies (\n                      <jats:italic>I\u00b2<\/jats:italic>\n                      =97.45%; 95%\u2009CI for\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      97.15 to 97.72). Subgroup analysis revealed that patients treated with platinum-based agents and taxanes had the highest prevalence of chronic moderate-to-severe CIPN or painful CIPN (44.47% and 55.68%, respectively), and among primary cancers, those with breast cancer, multiple myeloma, and lung cancer reported the highest prevalence of chronic moderate-to-severe CIPN or painful CIPN (61.31%, 53.55%, and 50.85%, respectively). Study design, HDI, and publication year were non-significant moderators of prevalence estimates. Based on our Grading of Recommendations, Assessment, Development, and Evaluation assessment, the certainty of evidence was considered \u201cvery low.\u201d Sensitivity analysis restricted to studies explicitly measuring painful CIPN (40.78%; 95%\u2009CI 29.08 to 52.74) or moderate-to-severe CIPN (49.04%; 95%\u2009CI 37.16 to 60.95) yielded similar prevalence estimates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides the first comprehensive global estimate of the prevalence of chronic moderate-to-severe CIPN or painful CIPN, highlighting its significant burden on patients worldwide. The variation in prevalence across geographical regions, chemotherapy regimens, and primary cancers underscores the need for tailored management strategies and further research to address potential disparities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rapm-2024-106229","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:40:19Z","timestamp":1738132819000},"page":"rapm-2024-106229","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":53,"title":["Global estimates of prevalence of chronic painful neuropathy and moderate-to-severe neuropathy among patients with chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of data from 29 countries between 2000 and 2024"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4601-9837","authenticated-orcid":false,"given":"Ryan S","family":"D'Souza","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Saini","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Rush University Medical Center, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-1002","authenticated-orcid":false,"given":"Nasir","family":"Hussain","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus, Ohio, USA"},{"name":"The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1028-8904","authenticated-orcid":false,"given":"Saba","family":"Javed","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Prokop","sequence":"additional","affiliation":[{"name":"Mayo Clinic Libraries, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeng F","family":"Her","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"2025120411201217000_rapm-2024-106229v3.1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3892\/br.2017.851","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"6","author":"Zhang","year":"2017","journal-title":"Biomed Rep"},{"key":"2025120411201217000_rapm-2024-106229v3.2","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719839025","article-title":"Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis","volume":"10","author":"Song","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"2025120411201217000_rapm-2024-106229v3.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.0914"},{"key":"2025120411201217000_rapm-2024-106229v3.4","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"2025120411201217000_rapm-2024-106229v3.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399"},{"key":"2025120411201217000_rapm-2024-106229v3.6","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-023-01107-4"},{"key":"2025120411201217000_rapm-2024-106229v3.7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14656566.2022.2060741","article-title":"The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain","volume":"23","author":"D\u2019Souza","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"2025120411201217000_rapm-2024-106229v3.8","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081909","article-title":"Neuromodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review","volume":"10","author":"D\u2019Souza","year":"2022","journal-title":"Biomedicines"},{"key":"2025120411201217000_rapm-2024-106229v3.9","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.neurom.2024.06.006","article-title":"Psychophysical and Functional Outcomes in Chemotherapy-induced Peripheral Neuropathy After Spinal Cord Stimulation: A Narrative Review and Case Series","volume":"27","author":"Vu","year":"2024","journal-title":"Neuromodulation"},{"key":"2025120411201217000_rapm-2024-106229v3.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020"},{"key":"2025120411201217000_rapm-2024-106229v3.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025120411201217000_rapm-2024-106229v3.12","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2023-104802"},{"key":"2025120411201217000_rapm-2024-106229v3.13","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2023-104801"},{"key":"2025120411201217000_rapm-2024-106229v3.14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1213\/ANE.0000000000006573","article-title":"Systematic Reviews and Meta-analyses in Regional Anesthesia and Pain Medicine (Part I): Guidelines for Preparing the Review Protocol","volume":"138","author":"Barrington","year":"2024","journal-title":"Anesth Analg"},{"key":"2025120411201217000_rapm-2024-106229v3.15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1213\/ANE.0000000000006607","article-title":"Systematic Reviews and Meta-analyses in Regional Anesthesia and Pain Medicine (Part II): Guidelines for Performing the Systematic Review","volume":"138","author":"D\u2019Souza","year":"2024","journal-title":"Anesth Analg"},{"key":"2025120411201217000_rapm-2024-106229v3.16","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000160"},{"key":"2025120411201217000_rapm-2024-106229v3.17","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1755","article-title":"Human development index in a context of human development: Review on the western Balkans countries","volume":"10","author":"Dasic","year":"2020","journal-title":"Brain Behav"},{"key":"2025120411201217000_rapm-2024-106229v3.18","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2013-203104"},{"key":"2025120411201217000_rapm-2024-106229v3.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2015.05.009"},{"key":"2025120411201217000_rapm-2024-106229v3.20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/XEB.0000000000000125","article-title":"Meta-analysis in evidence-based healthcare: a paradigm shift away from random effects is overdue","volume":"15","author":"Doi","year":"2017","journal-title":"Int J Evid Based Healthc"},{"key":"2025120411201217000_rapm-2024-106229v3.21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"key":"2025120411201217000_rapm-2024-106229v3.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"2025120411201217000_rapm-2024-106229v3.23","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2020-101960"},{"key":"2025120411201217000_rapm-2024-106229v3.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2025120411201217000_rapm-2024-106229v3.25","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E14-04-0916"},{"key":"2025120411201217000_rapm-2024-106229v3.26","first-page":"S26","article-title":"Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment","volume":"24 Suppl 2","author":"Staff","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"2025120411201217000_rapm-2024-106229v3.27","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-021-00377-z","article-title":"Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors","volume":"5","author":"Knoerl","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"2025120411201217000_rapm-2024-106229v3.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-14870-y","article-title":"Incidence density and factors associated with peripheral neuropathy among women with breast cancer during taxane-based chemotherapy","volume":"12","author":"Rattanakrong","year":"2022","journal-title":"Sci Rep"},{"key":"2025120411201217000_rapm-2024-106229v3.29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143710","article-title":"Current Challenges and Future Advances in Lung Cancer: Genetics, Instrumental Diagnosis and Treatment","volume":"15","author":"Vicidomini","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025120411201217000_rapm-2024-106229v3.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09441-3","article-title":"Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study","volume":"22","author":"Miyawaki","year":"2022","journal-title":"BMC Cancer"},{"key":"2025120411201217000_rapm-2024-106229v3.31","first-page":"1","article-title":"Anthracyclines in the treatment of cancer. An overview","volume":"54 Suppl 4","author":"Hortob\u00e1gyi","year":"1997","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025120411201217000_rapm-2024-106229v3.32","doi-asserted-by":"crossref","first-page":"91238","DOI":"10.18632\/oncotarget.20437","article-title":"Comparative efficacy of different chemotherapies for non-Hodgkin lymphoma: a network-meta analysis","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"key":"2025120411201217000_rapm-2024-106229v3.33","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae012","article-title":"Opioid use in cancer patients compared with noncancer pain patients in a veteran population","volume":"8","author":"Mudumbai","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"2025120411201217000_rapm-2024-106229v3.34","doi-asserted-by":"crossref","first-page":"104665","DOI":"10.1016\/j.jpain.2024.104665","article-title":"Nationally Representative Rates of Incident Prescription Opioid Use Among United States Adults and Selected Subpopulations: Longitudinal Cohort Study From the National Health Interview Survey, 2019 to 2020","volume":"25","author":"D\u2019Souza","year":"2024","journal-title":"J Pain"},{"key":"2025120411201217000_rapm-2024-106229v3.35","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200077"}],"updated-by":[{"DOI":"10.1136\/rapm-2024-106229corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000}}],"container-title":["Regional Anesthesia &amp; Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rapm-2024-106229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T19:20:23Z","timestamp":1764876023000},"score":1,"resource":{"primary":{"URL":"https:\/\/rapm.bmj.com\/lookup\/doi\/10.1136\/rapm-2024-106229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":35,"alternative-id":["10.1136\/rapm-2024-106229"],"URL":"https:\/\/doi.org\/10.1136\/rapm-2024-106229","relation":{},"ISSN":["1098-7339","1532-8651"],"issn-type":[{"value":"1098-7339","type":"print"},{"value":"1532-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]}}}